Marker Therapeutics, Inc. (MRKR) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Marker Therapeutics, Inc. (MRKR) Bundle
Looking to assess Marker Therapeutics, Inc.'s (MRKR) intrinsic value? Our (MRKR) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | .5 | 1.2 | 9.0 | 3.3 | 5.3 | 8.4 | 13.4 | 21.3 | 33.9 |
| Revenue Growth, % | 0 | 118.95 | 166.01 | 625.17 | -63.23 | 59.19 | 59.19 | 59.19 | 59.19 | 59.19 |
| EBITDA | -22.0 | -27.6 | -36.3 | -19.8 | -11.8 | -5.3 | -8.4 | -13.4 | -21.3 | -33.9 |
| EBITDA, % | -10332.86 | -5919.3 | -2924.62 | -219.79 | -356.14 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .3 | 1.1 | 3.2 | 3.7 | 2.8 | 4.5 | 7.1 | 11.4 | 18.1 | 28.8 |
| Depreciation, % | 134.42 | 230.44 | 254.7 | 40.87 | 84.23 | 85.02 | 85.02 | 85.02 | 85.02 | 85.02 |
| EBIT | -22.3 | -28.7 | -39.5 | -23.5 | -14.6 | -5.3 | -8.4 | -13.4 | -21.3 | -33.9 |
| EBIT, % | -10467.28 | -6149.74 | -3179.32 | -260.66 | -440.37 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 43.9 | 21.4 | 42.4 | 11.8 | 15.1 | 5.3 | 8.4 | 13.4 | 21.3 | 33.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | 1.0 | .0 | 2.4 | 1.0 | 1.9 | 3.1 | 4.9 | 7.8 | 12.5 |
| Account Receivables, % | 26.36 | 214.35 | 0.01908658 | 26.68 | 31.04 | 36.82 | 36.82 | 36.82 | 36.82 | 36.82 |
| Inventories | .0 | -1.0 | .0 | .0 | -1.0 | -1.4 | -2.2 | -3.5 | -5.5 | -8.8 |
| Inventories, % | 0 | -214.23 | 0 | 0 | -29.84 | -25.97 | -25.97 | -25.97 | -25.97 | -25.97 |
| Accounts Payable | 1.0 | 2.9 | 5.1 | 1.1 | 1.0 | 3.6 | 5.7 | 9.1 | 14.5 | 23.1 |
| Accounts Payable, % | 465.77 | 628.77 | 414.27 | 12.23 | 29.02 | 68.25 | 68.25 | 68.25 | 68.25 | 68.25 |
| Capital Expenditure | -.4 | -10.4 | -3.1 | -4.9 | .0 | -3.7 | -6.0 | -9.5 | -15.1 | -24.0 |
| Capital Expenditure, % | -175.89 | -2233.99 | -252.16 | -54.92 | 0 | -70.98 | -70.98 | -70.98 | -70.98 | -70.98 |
| Tax Rate, % | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 | -0.02617108 |
| EBITAT | -21.2 | -28.5 | -39.5 | -23.5 | -14.6 | -5.2 | -8.3 | -13.2 | -21.0 | -33.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.3 | -35.9 | -37.2 | -31.2 | -9.6 | -2.4 | -5.3 | -8.5 | -13.5 | -21.5 |
| WACC, % | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -33.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -22 | |||||||||
| Terminal Value | -231 | |||||||||
| Present Terminal Value | -134 | |||||||||
| Enterprise Value | -168 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | -153 | |||||||||
| Diluted Shares Outstanding, MM | 9 | |||||||||
| Equity Value Per Share | -17.32 |
What You Will Get
- Real MRKR Financial Data: Pre-filled with Marker Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Marker Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Marker Therapeutics’ historical financial reports and projected forecasts.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Marker Therapeutics’ intrinsic value update instantly.
- Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A robust tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Marker Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Marker Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Marker Therapeutics, Inc. (MRKR)?
- Innovative Therapies: Pioneering treatments that utilize cutting-edge technology in immunotherapy.
- Strong Pipeline: A robust portfolio of clinical-stage assets aimed at addressing unmet medical needs.
- Expert Team: Led by seasoned professionals with extensive experience in biopharmaceutical development.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
- Positive Impact: Focused on improving patient outcomes and enhancing the quality of life.
Who Should Use This Product?
- Healthcare Professionals: Understand advanced treatment methodologies and their implications using real-world data.
- Researchers: Integrate cutting-edge models into clinical studies or academic projects.
- Investors: Validate your investment hypotheses and assess valuation scenarios for Marker Therapeutics, Inc. (MRKR).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Biotech Entrepreneurs: Learn from the valuation strategies of established companies like Marker Therapeutics, Inc. (MRKR).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Marker Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Marker Therapeutics, Inc. (MRKR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.